282 related articles for article (PubMed ID: 23962908)
1. PharmGKB summary: tamoxifen pathway, pharmacokinetics.
Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE
Pharmacogenet Genomics; 2013 Nov; 23(11):643-7. PubMed ID: 23962908
[No Abstract] [Full Text] [Related]
2. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
3. Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.
Young D
Am J Health Syst Pharm; 2006 Dec; 63(23):2286, 2296. PubMed ID: 17105997
[No Abstract] [Full Text] [Related]
4. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
[TBL] [Abstract][Full Text] [Related]
5. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
[TBL] [Abstract][Full Text] [Related]
6. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
Higgins MJ; Stearns V
Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
[No Abstract] [Full Text] [Related]
7. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and CYP2D6: a contradiction of data.
Hertz DL; McLeod HL; Irvin WJ
Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
[TBL] [Abstract][Full Text] [Related]
10. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
12. Personalized tamoxifen: a step closer but miles to go.
Bardia A; Stearns V
Clin Cancer Res; 2010 Sep; 16(17):4308-10. PubMed ID: 20651057
[TBL] [Abstract][Full Text] [Related]
13. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Pritchard KI
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S18. PubMed ID: 21172080
[No Abstract] [Full Text] [Related]
14. Genetics and drug interactions affect tamoxifen metabolism.
McCaffrey P
Lancet Oncol; 2005 Feb; 6(2):72. PubMed ID: 15704296
[No Abstract] [Full Text] [Related]
15. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of anti-estrogen treatment of breast cancer.
Del Re M; Michelucci A; Simi P; Danesi R
Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
[No Abstract] [Full Text] [Related]
18. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues.
Kim SJ; Kang HS; Jung SY; Min SY; Lee S; Kim SW; Kwon Y; Lee KS; Shin KH; Ro J
J Mol Med (Berl); 2010 Nov; 88(11):1123-31. PubMed ID: 20628863
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]